

IDEXX LABORATORIES INC /DE  
 Form 4  
 August 25, 2008

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**RAINES MERILEE**

2. Issuer Name and Ticker or Trading Symbol  
**IDEXX LABORATORIES INC /DE [IDXX]**

5. Relationship of Reporting Person(s) to Issuer  
 (Check all applicable)

(Last) (First) (Middle)  
**C/O IDEXX LABORATORIES, INC., ONE IDEXX DRIVE**  
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)  
**08/22/2008**

\_\_\_\_ Director \_\_\_\_\_ 10% Owner  
 Officer (give title below) \_\_\_\_\_ Other (specify below)  
 Corporate Vice President & CFO

**WESTBROOK, ME 04092**

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 \_\_\_ Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |   |        | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |            |       |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--------|---|--|-----------------------------------|------------|-------|
|                                 |                                      |  |                                | Code  | V | Amount |   |  |                                   | (A) or (D) | Price |
| Common Stock                    | 08/22/2008                           |  | M                              |   |   | 12,414 | A   | \$ 12.25   | 118,221                           | D          |       |
| Common Stock                    | 08/22/2008                           |  | M                              |   |   | 6,586  | A   | \$ 12.25   | 124,807                           | D          |       |
| Common Stock                    | 08/22/2008                           |  | M                              |   |   | 21,000 | A   | \$ 12.25   | 145,807                           | D          |       |
| Common Stock                    | 08/22/2008                           |  | S                              |   |   | 21,000 | D   | \$ 57.3352   | 124,807                           | D          |       |
|                                 |                                      |  |                                |   |   |        |   | <u>(1)</u>   |                                   |            |       |

# Edgar Filing: IDEXX LABORATORIES INC /DE - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Security (Instr. 3 and 4) | Amount or Number of Shares |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|----------------------------|
| Incentive Stock Option (right to buy)      | \$ 12.25   | 08/22/2008                           |  | M                              | 12,414  | <u>(2)</u> 02/03/2009                                    | Common Stock  | 12,414                     |
| Non-Qualified Stock Option (right to buy)  | \$ 12.25   | 08/22/2008                           |  | M                              | 6,586   | <u>(3)</u> 02/03/2009                                    | Common Stock  | 6,586                      |
| Non-Qualified Stock Option (right to buy)  | \$ 12.25   | 08/22/2008                           |  | M                              | 21,000  | <u>(3)</u> 02/03/2009                                    | Common Stock  | 21,000                     |

## Reporting Owners

| Reporting Owner Name / Address   | Relationships |           |                                |       |
|--|---------------|-----------|--------------------------------|-------|
|  | Director      | 10% Owner | Officer                        | Other |
| RAINES MERILEE<br>C/O IDEXX LABORATORIES, INC.<br>ONE IDEXX DRIVE<br>WESTBROOK, ME 04092 |               |           | Corporate Vice President & CFO |       |

## Signatures

John B. Rogers, Attorney-in-Fact for Merilee Raines 08/25/2008

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

## Edgar Filing: IDEXX LABORATORIES INC /DE - Form 4

- The sales price reported above reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged
- (1) between \$57.20 and \$57.60. Reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
  - (2) Grant of option to buy shares of Common stock exercisable as to 722 shares on 2/03/2002, 3,692 shares on 2/03/2003 and 8,000 shares on 2/03/2004.
  - (3) Grant of option to buy shares of Common stock exercisable as to 8,000 shares on 2/03/2000 and 2/03/2001, 7,278 shares on 2/03/2002 and 4,308 shares on 2/03/2003.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.